On Monday, Syros Pharmaceuticals Inc (NASDAQ: SYRS) opened lower -12.28% from the last session, before settling in for the closing price of $0.29. Price fluctuations for SYRS have ranged from $0.18 to $8.17 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 128.79%. Company’s average yearly earnings per share was noted 73.32% at the time writing. With a float of $17.25 million, this company’s outstanding shares have now reached $26.45 million.
Let’s determine the extent of company efficiency that accounts for 68 employees. In terms of profitability, gross margin is -228.76%, operating margin of -28892.23%, and the pretax margin is -25340.67%.
Syros Pharmaceuticals Inc (SYRS) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Syros Pharmaceuticals Inc is 35.70%, while institutional ownership is 49.17%. The most recent insider transaction that took place on Nov 25 ’24, was worth 26,943. Before that another transaction happened on Nov 18 ’24, when Company’s Chief Development Officer sold 36,133 for $0.22, making the entire transaction worth $7,949. This insider now owns 0 shares in total.
Syros Pharmaceuticals Inc (SYRS) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -2.22 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -1.12) by -1.1. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.7 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 73.32% per share during the next fiscal year.
Syros Pharmaceuticals Inc (NASDAQ: SYRS) Trading Performance Indicators
Check out the current performance indicators for Syros Pharmaceuticals Inc (SYRS). In the past quarter, the stock posted a quick ratio of 2.25. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 19.96.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.03, a number that is poised to hit -0.69 in the next quarter and is forecasted to reach -2.05 in one year’s time.
Technical Analysis of Syros Pharmaceuticals Inc (SYRS)
Looking closely at Syros Pharmaceuticals Inc (NASDAQ: SYRS), its last 5-days average volume was 79.79 million, which is a jump from its year-to-date volume of 2.36 million. As of the previous 9 days, the stock’s Stochastic %D was 12.86%. Additionally, its Average True Range was 0.28.
During the past 100 days, Syros Pharmaceuticals Inc’s (SYRS) raw stochastic average was set at 1.10%, which indicates a significant decrease from 2.31% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 854.87% in the past 14 days, which was higher than the 375.94% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.8203, while its 200-day Moving Average is $4.2775. However, in the short run, Syros Pharmaceuticals Inc’s stock first resistance to watch stands at $0.2857. Second resistance stands at $0.3143. The third major resistance level sits at $0.3296. If the price goes on to break the first support level at $0.2418, it is likely to go to the next support level at $0.2265. Now, if the price goes above the second support level, the third support stands at $0.1979.
Syros Pharmaceuticals Inc (NASDAQ: SYRS) Key Stats
There are currently 26,832K shares outstanding in the company with a market cap of 7.79 million. Presently, the company’s annual sales total 9,940 K according to its annual income of -164,570 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -6,400 K.
